ABSTRACT
Objective To explore the radiation dose from body γ-knife treatment to the nontargeted region's sensitive organs before and after shielding.Methods 20 patients suffering tumors less than 5 cm were selected.Calibrated thermoluminescence dosimeters (TLD) were placed above the sensitive organs,such as lens,thyroid gland and sexual gland,to measure the radiation dose received before shielding.Different plans were prepared for the patients with lung and renicapsule tumors using calibrators of different size.Radiation dose was measured by the aid of water phantom.For selected lungtumor treatment plan,the radiation doses were measured at the same location on the water phantom shielded with and without 1,2 and 4 cm lead,respectively.Results The maximum doses were 1 023.3 mGy for lens,1 235.7 mGy for thyroid gland and 1 176.8 mGy for sexual glands after treatment,respectively,being higher on the left site than the right.The radiation doses to the sensitive organs were higher for the water phatom with more tartgted points,decreasing by 55％-91％ after being covered with 1,2 and 4 cm lead shieldings.There were significant differences in doses received before and after lead shielding (t =14.4,12.9,13.3,P ＜ 0.05).Conclusions In the course of body γ-knife treatment,the additional factors would increase the dose to the sensitive organs.Therefore,it is necessary to provide lead shielding protection to the teenagers and adults with fertility when they undergo body γ-knife treatment.Trial registration Chinese Clinical Trial Registry,ChiCTR-OOC-16008259.
ABSTRACT
Objective To observe the change of 18F-Fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) imaging on lung tumors after treatment of Argon-Helium (Ar-He) cryoablation,and to search the measure for evaluating the short-term curative effect after treatment of Ar-He cryoablation.Methods 19 focuses of 15 patients had completed the treatment of Ar-He cryoablation.All of patients imaged with 18F-FDG PET-CT in six months after Ar-He cryoablation.7 patients of all imaged with 18F-FDG PET-CT pre- and after Ar-He cryoablation.The others only imaged with 18F-FDG PET-CT after cryoablation,but these focuses could compare with tissues near the focus or other tumors in themselves.Results 18F-FDG PET-CT imaging found that there was no accumulation of radionuclide in 13 of 19 focuses after cryoablation and there was no new tumor in follow-up.Two target region of cryoablation,which grew up in mediastinum,were found radiation defect with distinct boundary and expanding outward during 4 months.The other 4 focuses recurred during 6 months in which there was accumulation of radionuclide after cryoablation.There was significant change about SUVmax of focuses after cryoablation by qualitative and quantitative analysis (t =3.784,P ＜0.05).But the changes of SUVmax had no significant difference in different time,between cryoablation and PET-CT imaging (F =0.106,P ＞0.05).Conclusion 18F-FDG PET-CT imaging really reveals the range and effect of Ar-He cryoablation.It is an optimal measure for evaluating the short term curative effect after Ar-He cryoablation.
ABSTRACT
OBJECTIVE To observe the feasibility and safety of cryoablation of cervical lymph node metastases for nonsurgical candidates.METHODS The procedure was performed after achievement of local anesthesia for 15 cases.In this clinical study,local anesthesia with no sedation was performed to all the patients.In all cases,patients underwent two freeze/thaw cycles.RESULTS Tumors of 14 patients were thoroughly covered by ice balls.In one patient,96% of the tumorous lesion was covered by ice balls.In these patients,no complicated complication was observed during the treatment.CONCLUSION Percutaneous cryoablation therapy for cervical lymph node metastases under ultrasonic guidance is a feasible and minimally invasive method with satisfactory local control.
ABSTRACT
Objective To evaluate the effect and clinical value of ultrasonography-guided Argon-Helium targeted ablation on treatment of liver tumor.Methods By means of ultrasound inducing,217 patients of liver tumors were selected for percutaneous Argon-Helium targeted cryoablation.Results All of liver hemangioma shrank in different degrees after cryoablation; 12 cases of small hepatic cancer were followed up for over one year,the one-year survival rate was 83.3% (10/12). 82.1% (165/201) advanced patients became better and clinical symptom ameliorated.One hundred and seventy-five cases of advanced patients were followed up for over one year,the one-year survival rate was 69.7% (122/175).The common complications after Argon-Helium cryoablation treatment were hemorrhage( 3.7% ,8/217), pleural effusion( 2.8% , 5/217). Conclusions Ultrasound-guided Argon-Helium targeted ablation in treatment of liver tumor is simple,safe and effective.